<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04963244</url>
  </required_header>
  <id_info>
    <org_study_id>2018-099</org_study_id>
    <nct_id>NCT04963244</nct_id>
  </id_info>
  <brief_title>Biomarker of Acute Exacerbation of COPD</brief_title>
  <official_title>Biomarker of Acute Exacerbation of COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is the main factor that&#xD;
      leads to the deterioration of the disease. Currently, the diagnosis of AECOPD mainly relies&#xD;
      on clinical manifestations, and good predictors or biomarkers are lacking. This study aims to&#xD;
      explain the gene expression changes related to the disease at the transcriptional level and&#xD;
      validate it in multiple levels, reveal specific biomarkers and potential pathogenesis, to&#xD;
      provide a research basis for the diagnosis and treatment of AECOPD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differentially expressed genes of 13 participants as assessed by RNA sequencing</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">92</enrollment>
  <condition>COPD Exacerbation</condition>
  <arm_group>
    <arm_group_label>AECOPD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable COPD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stable COPD and AECOPD and healthy controls were recruited from the Second&#xD;
        Affiliated Hospital of Zhejiang University School of Medicine and Yuhang District of the&#xD;
        Second Affiliated Hospital of Zhejiang University, Hangzhou, China.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For stable COPD:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Over 40 years old.&#xD;
&#xD;
          2. in line with the diagnostic criteria in GOLD 2018.&#xD;
&#xD;
          3. with the ability to sign informed consent.&#xD;
&#xD;
          4. can be followed up according to the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. with other pulmonary diseases (such as lung cancer, sarcoidosis, tuberculosis,&#xD;
             pulmonary fibrosis, cystic fibrosis) and severe Î±1-antitrypsin deficiency.&#xD;
&#xD;
          2. with other inflammatory diseases (such as rheumatoid arthritis and inflammatory bowel&#xD;
             disease, etc.).&#xD;
&#xD;
          3. a history of pulmonary surgery, or a diagnosis of malignant tumor recently.&#xD;
&#xD;
          4. a history of blood transfusion in 4 weeks.&#xD;
&#xD;
          5. participating in a double-blind drug clinical trial.&#xD;
&#xD;
          6. unable to walk.&#xD;
&#xD;
          7. using oral or intravenous steroid therapy.&#xD;
&#xD;
          8. with acute exacerbation in 4 weeks.&#xD;
&#xD;
        For AECOPD:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Patients who were over 40 years old were eligible for inclusion if they had a diagnosis of&#xD;
        COPD in their primary care clinical record and were presenting with an acute exacerbation&#xD;
        of respiratory symptoms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other specific diseases that may account for sudden changes in respiratory symptoms&#xD;
             should be excluded by clinical or laboratory tests.&#xD;
&#xD;
          2. The remaining exclusion criteria were consistent with the above five criteria in&#xD;
             stable COPD.&#xD;
&#xD;
        The control group:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Healthy people over 40 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        with chronic airway diseases and other lung diseases, and heart, kidney, liver, and other&#xD;
        important organ diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the Second Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <keyword>acute exacerbation</keyword>
  <keyword>transcriptomic</keyword>
  <keyword>pathogenesis</keyword>
  <keyword>biomarkers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

